TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

371 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

150 studies on the map

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) — Phoenix Children's Hospital, PhoenixStudy to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab — TG Therapeutics Investigational Trial Site, BirminghamA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis — AllerVie Clinical Research, BirminghamEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. — Perseverance Research Center, ScottsdaleThis Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment — Cahaba Dermatology & Skin Health Center- Site Number : 8400006, BirminghamA Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis — Applied Research Center Of Arkansas /ID# 268547, Little RockA Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis — AllerVie Clinical Research, BirminghamA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis — Alabama Neurology Associates PC, BirminghamA Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) — TG Therapeutics Investigational Trial Site, BirminghamReal-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults — Galderma Investigational Site - 8893, BirminghamA Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis — Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute, PhoenixA Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis — Investigational Site, Fountain ValleyA Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) — Arizona Liver Health - Chandler, ChandlerBest Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) — Stanford Multiple Sclerosis Center, Palo AltoTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO — University of Alabama at Birmingham Cancer Center, BirminghamA Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) — Local Institution - 0011, BirminghamA Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) — Arizona Liver Health, ChandlerNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis — North Central Neurology Associates- Site Number : 8401100, CullmanA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. — Research Site, SurpriseA Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity — Alabama Neurology Associates, BirminghamPlatform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis — Novartis Investigative Site, BirminghamA Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis — Allervie Clinical Research, BirminghamStudy of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis — Enveda Investigative Site, BirminghamA Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition — Arizona Liver Health, ChandlerA Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis — Atd002 52021, OceansideA Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis — Inmagene Site 1, LancasterStudy to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH — University of California San Diego, La JollaA Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis — Leo Pharma Investigational site, BirminghamA Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH — GSK Investigational Site, ChandlerA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis — Arizona Neuroscience Research, LLC, PheonixSPYRAL GEMINI Pilot Study — Stanford Hospital and Clinics, StanfordOcrelizumab Discontinuation in Relapsing Multiple Sclerosis — Yale School of Medicine, New HavenA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH — GSK Investigational Site, ArcadiaA Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH — GSK Investigational Site, ArcadiaStudy to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis — Local Institution - 0114, Loma LindaA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis — Arizona Neuroscience Research, LLC, PhoenixA Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease — Knowledge Research Center, OrangeA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH — Akero Clinical Study Site, BirminghamA Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure — Research Site, FairhopeA Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) — Profound Research, LLC, CarlsbadA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab — Cahaba Dermatology & Skin Health Center /ID# 263855, BirminghamA Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema — Cahaba Dermatology & Skin Health Center, LLC, BirminghamAn Open-label Study of AZD0120 in Adults With Multiple Sclerosis — Research Site, TucsonEASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Pinnacle Research Group, LLC, AnnistonA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) — 89bio Clinical Study Site, BirminghamLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — University of Alabama at Birmingham, BirminghamA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH — 89bio Clinical Study Site, BirminghamA Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema — Cahaba Dermatology & Skin Health Center, BirminghamA 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis — Sitryx Clinical Site, Arkansas CityTargeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) — University of California, San Diego: Dermatology Clinical Trials Unit, San DiegoNon-Invasive Quantification of Liver Health in NASH (N-QUAN) — Arizona Liver Health, ChandlerThe SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study — Shepherd Center, AtlantaCare in Multiple Sclerosis (MS) — University of Alabama at Birmingham, BirminghamConfirmatory Trial for Alleviating Fatigue in Multiple Sclerosis — Washington VA Medical Center, Washington D.C.LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — The Institute for Liver Health II DBA Arizona Clinical Trials, PeoriaA Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis — Akero Clinical Study Site, BirminghamA Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis — Stanford University Medical Center, StanfordA Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years — Boston Clinical Trials Inc - Internal Medicine, BostonA Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis — Profound Research, LLC, CarlsbadBreathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH — Rocky Mountain Regional VA Medical Center, Aurora, CO, AuroraA Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk — PROVIDE Virtual Research Coordination Center, San FranciscoFibrosis Lessens After Metabolic Surgery — Banner Health Center, PhoenixA Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases — Stanford Neuroscience Health Center, Palo AltoGenes and Environment in Multiple Sclerosis — National Institute of Neurological Disorders and Stroke, BethesdaEvaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares — U.S. Dermatology Partners, PhoenixA Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis — Hamilton Research, LLC, AlpharettaA Study of LY3971297 in Healthy Participants — CenExel ACT, AnaheimEvaluation of Non-Invasive Tests for Metabolic Liver Disease — Clinical Pharmacology of Miami, MiamiVertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis — University of San Fransisco, San FranciscoA Study of Efimosfermin Alfa in Adults With Hepatic Impairment — GSK Investigational Site, RialtoProspective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod — University of Colorado Anschutz Medical Campus, AuroraCentral Vein Sign in Multiple Sclerosis Extension Study — Cedars-Sinai Medical Center, Los AngelesFIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients — Anaheim Clinical Trials, LLC, AnaheimEvaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis — First OC Dermatology, Fountain ValleyA Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) — First OC Dermatology, IrvineA Study to Learn About Study Medicine Called PF-08049820 in People With Eczema — Northridge Clinical Trials, NorthridgePregnancy Exposure Registry for Vumerity (Diroximel Fumarate) — University of Colorado Anschutz Medical Campus, AuroraStudy to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis — Minneapolis Clinic of Neurology, Golden ValleyLebrikizumab in Moderate-to-severe Atopic Dermatitis — Physioseq USA - CA, FolsomMilitary Health and Nutrition Examination Study — Fort Campbell, Fort CampbellA Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities — Unity Health Care, Washington D.C.Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers — UCSF, San FranciscoMultiple Sclerosis Implementation Network (Registry) — Multiple Sclerosis Association of America, Cherry HillA Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis — Arkansas Research Trials, North Little RockSafety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis — Red River Research Partners, FargoEffect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial — Brigham and Women's Hospital, BostonPredicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis — Mayo Clinic in Rochester, RochesterEndoscopic Ultrasound Shear Wave Elastography Study — Brigham and Women's Hospital, BostonAndrogens and NAFLD Longitudinal Cohort Study — University of California San Francisco, San FranciscoTargeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis — Johns Hopkins University, BaltimoreHigh-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis — Rehabilitation Hospital of Indiana, IndianapolisTreatment of Participants With Primary or Secondary Progressive Multiple Sclerosis — University of Kansas Medical Center, Kansas CityA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab — Physioseq, LLC /ID# 267266, SacramentoObe-cel in Refractory Progressive Forms of Multiple Sclerosis — Stanford University, Redwood CityA Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) — Arizona Liver Health, ChandlerA Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors — UConn Health, FarmingtonIntegrating Free-choice Marketplace, dieTitian coacHing, cultuRally Tailored messagIng to improVE Blood Pressure — Johns Hopkins Community Physicians, BaltimoreSocial Needs Screening and Chronic Diseases Study (WE CARE) — UMass Memorial Medical Center - Hahnemann Campus, WorcesterA Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring — Evidera INC., BethesdaPrepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS? — Jacobs School of Medicine and Biomedical Sciences, Neurology, University at Buffalo, BuffaloEndoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease — Brigham and Women's Hospital, BostonThe Sweet Kids Study (Stevia on Weight and Energy Effect Over Time) — Arkansas Children's Nutrition Center, Little RockAddressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US — Duke University - Charlotte Study Sites, CharlotteQuantifying Hepatic Mitochondrial Fluxes in Humans — Texas Diabetes Institute - University Health System, San AntonioDigoxin In NASH (CODIN) — Yale New Haven Health, New HavenReversal of Lipid-Induced Insulin Resistance — Magnetic Resonance Research Center (MRRC), New HavenPharmacy-led Transitions of Care Intervention to Improve Medication Adherence — University of Tennessee Medical Center, KnoxvilleCocooned Moms Study — University Of Miami, MiamiA Palliative Care Model Impact on Knowledge and Attitudes — Judith Jaffe Multiple Sclerosis Center, New YorkWearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study — Norman Fixel Institute for Neurological Diseases, GainesvilleEffects of Ublituximab on Motor Functions in Multiple Sclerosis — Georgia State University, AtlantaSodium in the Skin and Atopic Dermatitis — San Francisco VA Medical Center, San FranciscoThe Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis — University of Pittsburgh Medical Center, PittsburghBlood Collection Biorepository for Liver Disease Research — University at Buffalo, Buffalo General Medical Center, BuffaloHealthy Living Anson Study — University of North Carolina at Chapel Hill, Chapel HillGut Microbiota in Metabolic Surgery — Vanderbilt_University MC, NashvilleLifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients — West Virginia School of Osteopathic Medicine, LewisburgIntermittent Fasting for NAFLD in Adults — Massachusetts General Hospital, BostonSympathetic Mechanisms in Obesity-Crossover Design — Vanderbilt University Medical Center, NashvillePRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis — University of Alabama at Birmingham, BirminghamCardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension — Penn State Milton S. Hershey Medical Center, HersheyFeasibility of Semaglutide in Advanced Lung Disease — University of Pennsylvania Perelman School of Medicine, PhiladelphiaMetabolic Effects of Angiotensin-(1-7) — Vanderbilt University Medical Center, NashvilleSympathetic Transduction in Obesity-associated Hypertension (OB-HTN) — University of Texas Southwestern Medical Center, DallasHuman Models of Selective Insulin Resistance: Alpelisib, Part I — Columbia University Irving Medical Center, New YorkCommunity Park-Based Programs for Health Promotion: Fit2Play Prospective Cohort Study — Miami-Dade County Parks, Recreation and Open Spaces Department, MiamiInspire HER: Inspiring the Heart and Emotions for Radical Health — University of Alabama at Birmingham, BirminghamTargeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial — Sidney & Lois Eskenazi Hospital, IndianapolisCommunity Park-Based Programs for Health Promotion: Active Older Adults Prospective Cohort Study — Miami-Dade County Parks, Recreation and Open Spaces Department, MiamiSympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study) — University of Kansas Medical Center, Kansas CityOptimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease — Cleveland Clinic Main Campus, ClevelandEffect of Insulin Lowering on Lipogenesis — Columbia University Irving Medical Center, New YorkFacilitated Transitions From Postpartum to Primary Care Coordination for People With Chronic Conditions — Massachusetts General Hospital, BostonEarly Tracking of Childhood Health Determinants (ETCHED) Study — NIDDK, Phoenix, PhoenixPediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE) — Wake Forest Health Sciences, Winston-SalemPrescription of Step Counts for Targeted Changes in Body Composition and Cardiometabolic Risk in Overweight/Obese Adults — Kennesaw State Universityh, KennesawConical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients — Prentice Women's Hospital, ChicagoHarnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM) — University of Missouri School of Medicine, ColumbiaHarnessing Macrophage Lysosomal Lipid Metabolism in Obesity — University of Missouri School of Medicine, ColumbiaRoutine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD) — University of Missouri-Columbia, ColumbiaImpact GLP-1 Agonists Following Bariatric — University of Missouri Hospital, ColumbiaDiabetes and Heart Disease Risk in Blacks — National Institutes of Health Clinical Center, BethesdaPathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) — Yale New Haven Hospital, New HavenPeople With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists — Northwestern Memorial Hospital, ChicagoPreparing FIM-BCS - A Lifestyle Modification for African-American Breast Cancer Survivors — University of Illinois Chicago, ChicagoCARBON: UAB Cardiovascular Research Biobank — University of Alabama at Birmingham, BirminghamMitigating the Pro-inflammatory Phenotype of Obesity — University of Kansas Medical Center, Kansas CityBlack Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention — The Ohio State University, ColumbusLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance — Stanford University, StanfordInvestigating the Link Between Type 2 Immunity and NAFLD in Human Obesity — Mayo Clinic in Arizona, Scottsdale

Showing the 150 nearest — narrow your filters for fewer, closer studies.